Photoacoustic and ultrasound imaging of brown fat activity
Official title: Research on the Morphology and Functional Assessment of Brown Adipose Tissue With Photoacoustic Imaging
Run by Peking Union Medical College Hospital · NCT07327684 · Data updated 2026-11-12
This project will test a radiation-free photoacoustic and ultrasound scan to see if it can measure brown fat activity in healthy adults and people with metabolic syndrome.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 80 Years |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | Peking Union Medical College Hospital Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Beijing) |
| Status | Recruiting |
| Started | May 22, 2025 |
| Main results expected | December 31, 2026 |
| Study ends | December 31, 2027 |
| Registry record updated | January 8, 2026 |
| Trial ID | NCT07327684 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults over 18 with metabolic syndrome (and healthy volunteer controls) who can tolerate cold exposure and have no contraindications such as pregnancy, Raynaud's, significant cardiovascular disease, or recent use of sympathomimetic or sympatholytic drugs are ideal candidates.
✕Probably not a fit
People who are pregnant or lactating, have Raynaud's or intolerance to cold, have BMI ≥ 30, active cardiovascular or cerebrovascular disease, recent major weight change, or cannot attend on-site imaging visits are unlikely to qualify or benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This interventional protocol uses multi-wavelength photoacoustic imaging combined with ultrasound to capture brown adipose tissue (BAT) morphology and functional signals such as blood perfusion, lipid content, and oxygenation. Participants include healthy adults and people diagnosed with metabolic syndrome who will undergo scans at baseline and after controlled cold exposure to provoke BAT activation. The study aims to develop standardized, quantitative PAI parameters for BAT and compare those parameters between the two groups. Data will be collected noninvasively and compared with existing expectations from PET/CT-based BAT research to establish technical feasibility and reproducibility.
Why it matters
Potential benefit: If successful, this could provide a safe, repeatable, radiation-free imaging method to monitor brown fat function and help with early diagnosis or tracking of metabolic syndrome.
How similar studies have gone: Photoacoustic imaging of BAT is an emerging technique with promising early research showing it can detect perfusion and lipid signals, but it has not yet been validated as a clinical replacement for PET/CT.
Who can join: the full rules
Show full inclusion / exclusion criteria
Criteria for Healthy Subjects: (INCLUSION CRITERIA) 1. Healthy individuals over 18 years of age. 2. Body Mass Index (BMI) \< 30. 3. No history of metabolic diseases, rheumatic immune diseases, or cardiovascular and cerebrovascular diseases. 4. Not currently using any sympathomimetic or sympatholytic drugs. 5. Non-smoker and does not consume excessive alcohol. (EXCLUSION CRITERIA) 1. Weight change \> 5% within 3 months prior to enrollment. 2. BMI ≥ 30. 3. Diagnosis of metabolic disease, rheumatic immune disease, cardiovascular and cerebrovascular disease, or malignant tumor. 4. Use of sympathomimetic or sympatholytic drugs within 3 months prior to enrollment. 5. Smoker or consumes excessive alcohol. 6. Diagnosis of Raynaud's disease, or intolerance/allergy to cold stimulation. 7. Currently pregnant, lactating, or menstruating. 8. Contraindications to the injection of the radionuclide tracer Fluorodeoxyglucose (18F-FDG) or other conditions unsuitable for PET-CT examination. Criteria for Patients with Metabolic Syndrome and Insulin Resistance-Related Diseases: (INCLUSION CRITERIA) 1. Age between 18 and 60 years. 2. Must meet 3 or more of the following criteria: 1. Waist circumference ≥ 90 cm for males, ≥ 85 cm for females. 2. Fasting blood glucose ≥ 6.10 mmol/L (110 mg/dl) OR 2-hour postprandial blood glucose ≥ 7.80 mmol/L (140 mg/dl) OR previously diagnosed diabetes. 3. Blood pressure ≥ 130/85 mmHg OR previously diagnosed hypertension and under treatment. 4. Fasting triglycerides (TG) ≥ 1.7 mmol/L (150 mg/dl). 5. Fasting high-density lipoprotein cholesterol (HDL-C) \< 1.0 mmol/L (40 mg/dl). 3. Patients diagnosed with Polycystic Ovary Syndrome (PCOS), defined as meeting two or more of the following criteria and excluding other endocrine diseases that could cause similar symptoms: hyperandrogenism, ovulatory dysfunction, polycystic ovary morphology. (EXCLUSION CRITERIA) 1. Diagnosis of Type 1 diabetes or other specific types of diabetes. 2. Presence of acute diabetic complications or severe chronic diabetic complications. 3. History of acute or chronic pancreatitis, or pancreatic tumors. 4. Heart failure, unstable angina, myocardial infarction within the past 12 months, cerebral infarction, severe arrhythmia, or severe hypertension (blood pressure \> 180/110 mmHg despite antihypertensive medication). 5. Severe hepatic or renal dysfunction. 6. Comorbid malignant tumors or other severe chronic diseases. 7. Received glucose-lowering therapy within 3 months prior to enrollment OR a total of more than 3 months of glucose-lowering therapy in the past 2 years. 8. Diagnosis of rheumatic immune diseases. 9. Diagnosis of Raynaud's disease, or intolerance/allergy to cold stimulation. 10. Currently pregnant, lactating, or menstruating. 11. Contraindications to the injection of the radionuclide tracer Fluorodeoxyglucose (18F-FDG) or other conditions unsuitable for PET-CT examination.
Where it's running
-
Peking Union Medical College Hospital
Beijing, China Recruiting
Study contacts
- Study coordinator: Meng Yang, Doctor
- Email: yangmeng_pumch@126.com
- Phone: +8601060155493
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Asprosin and miRNA Profiles in Young Women with Metabolic Syndrome
This study tests whether certain blood biomarkers, including asprosin and six microRNAs, differ between young women with metabolic syndrome and healthy peers.
-
Kodo Millet Porridge and Gut Health in Overweight and Obese Adults
This study tests whether daily intake of Kodo millet porridge for 12 weeks can improve gut bacteria and metabolic health in adults who are overweight or obese.
-
Cranberry for gut and metabolic health in adults with overweight or obesity
This study will test whether drinking a cranberry beverage can improve blood sugar control, insulin sensitivity, blood lipids, and gut microbiota in adults with overweight or obesity who have metabolic risk factors.
-
Investigating fasting insulin and insulin resistance across different demographics
This study looks at how fasting insulin levels and insulin resistance vary among different groups of people based on age, sex, race, weight, and conditions like PCOS to better understand metabolic health.
-
Effects of weight loss with and without exercise on metabolic health
This study is testing whether losing weight with exercise helps improve metabolic health more than just losing weight through dieting alone for people with obesity.
-
Effects of exercise on fat tissue in obese individuals
This study tests how exercise affects fat tissue in people with obesity to see if it can help improve their metabolism and manage weight better.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.